IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?
Andy Gould, The Motley Fool
Sun, July 19, 2026 at 4:17 PM GMT+5:30
4 min read
- ^GSPC
-1.01%
Comparing the iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) and the VanEck Biotech ETF (NASDAQ:BBH) reveals two distinct fund profiles. IHE tracks established, blue chip pharmaceutical companies, while BBH zeroes in on the research-intensive biotech space. Here’s how those different strategies stack up in terms of cost, yield, and risk
Snapshot (cost & size)
Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-year return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield
The two funds are priced competitively — BBH carries a 0.35% expense ratio, while IHE charges 0.38%. There’s a bigger difference when it comes to income. IHE offers a notably higher yield, with a full 1-percentage-point advantage over BBH
Performance & risk comparison
What’s inside
Launched in 2006, IHE tracks a benchmark of domestic pharmaceutical stocks and currently holds 56 different securities. Its largest positions include Johnson & Johnson (NYSE:JNJ) at 22.44%, Eli Lilly (NYSE:LLY) at 22.3%, and Merck (NYSE:MRK) at 4.6%. By focusing on mature pharmaceutical firms, the fund offers a healthcare portfolio with lower price volatility than pure-play biotech funds
BBH aims to replicate the MVIS US Listed Biotech 25 Index, maintaining a lean portfolio of just 25 stocks. Its top holdings include Amgen (NASDAQ:AMGN) at 15.1%, Gilead Sciences (NASDAQ:GILD) at 12.8%, and Vertex Pharmaceuticals (NASDAQ:VRTX) at 9.1%. The fund specifically targets companies involved in genetic research and diagnostic technologies. BBH launched in 2011
For more guidance on ETF investing, check out the full guide at this link
What this means for investors
Choosing between these two ETFs is really a question of what role you want a healthcare fund to play in your portfolio
IHE is built for investors who want blue chip stability: its top two holdings alone, Johnson & Johnson and Eli Lilly, make up nearly 45% of the fund. This is a concentrated bet on a group of proven, profitable drugmakers with diversified revenue streams. That’s a big part of why it has held up better historically during downturns and pays a more attractive dividend
